Comprehensive investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH)

Shin Hayashi¹,²,³ *, Daniela Tiaki Uehara¹, Kousuke Tanimoto¹,⁴, Seiji Mizuno⁵, Yasutugu Chinen⁶, Shinobu Fukumura⁷, Jun-ichi Takanashi⁸, Hitoshi Osaka⁹, Nobuhiko Okamoto¹⁰, Johji Inazawa¹,²,¹¹ *

¹ Department of Molecular Cytogenetics, Medical Research Institute and Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ² Hard Tissue Genome Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³ Department of Neurobiology and Kavli Institute for Neuroscience, Yale University School of Medicine, New Haven, CT, United States of America, ⁴ Genome Laboratory, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan, ⁵ Department of Pediatrics, Central Hospital, Aichi Human Service Center, Kasugai, Japan, ⁶ Department of Pediatrics, University of the Ryukyus School of Medicine, Nishihara, Japan, ⁷ Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸ Department of Pediatrics, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan, ⁹ Department of Pediatrics, Jichi Medical School, Tochigi, Japan, ¹⁰ Department of Medical Genetics, Osaka Women's and Children's Hospital, Osaka, Japan, ¹¹ Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan

* shin.hayashi@yale.edu (SH); johinaz.cgen@mri.tmd.ac.jp (JI)

Abstract

The CASK gene (Xp11.4) is highly expressed in the mammalian nervous system and plays several roles in neural development and synaptic function. Loss-of-function mutations of CASK are associated with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH), especially in females. Here, we present a comprehensive investigation of 41 MICPCH patients, analyzed by mutational search of CASK and screening of candidate genes using an SNP array, targeted resequencing and whole-exome sequencing (WES). In total, we identified causative or candidate genomic aberrations in 37 of the 41 cases (90.2%). CASK aberrations including a rare mosaic mutation in a male patient, were found in 32 cases, and a mutation in ITPR1, another known gene in which mutations are causative for MICPCH, was found in one case. We also found aberrations involving genes other than CASK, such as HDAC2, MARCKS, and possibly HS3ST5, which may be associated with MICPCH. Moreover, the targeted resequencing screening detected heterozygous variants in RELN in two cases, of uncertain pathogenicity, and WES analysis suggested that concurrent mutations of both DYNC1H1 and DCTN1 in one case could lead to MICPCH. Our results not only identified the etiology of MICPCH in nearly all the investigated patients but also suggest that MICPCH is a genetically heterogeneous condition, in which CASK inactivating mutations appear to account for the majority of cases.
**Introduction**

The CASK gene (OMIM: *300172), which encodes a member of the MAGUK (membrane-associated guanylate kinase) protein family, is highly expressed in the mammalian nervous system of both adults and fetuses, and plays several roles in neural development and synaptic functions [1, 2]. Since 2008, when both a heterozygous deletion and point mutations affecting CASK were reported to cause intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH, OMIM: #300749) [3, 4], various types of CASK aberrations have been reported in more than 50 MICPCH patients [5, 6]. Due to its location on the X chromosome, loss-of-function of CASK usually leads to the manifestation of MICPCH in females, whereas a complete loss of this gene is believed to be lethal in males. Indeed, the vast majority of typical MICPCH by CASK aberrations are seen in female patients [4–8].

Since our first report [3], we have recruited 41 MICPCH patients to investigate their etiologies by genetic testing of CASK and other genome-wide approaches such as single nucleotide polymorphism (SNP) array, targeted resequencing and whole-exome sequencing. Besides 32 cases in which the molecular diagnosis could be attributed to CASK loss-of-function mutations, including a rare somatic mosaic mutation in a male patient, we identified a mutation in *ITPR1*, another gene in which mutations are causative for MICPCH. Moreover, in the analysis we identified aberrations in genes that might be associated with MICPCH: *HDAC2*, *MARCKS*, *RELN*, and possibly *HS3ST5*. Interestingly, our findings also suggested that concurrent mutations of both *DYNC1H1* and *DCTN1* might cause MICPCH. Our current study comprehensively clarified the etiologies of MICPCH in the cohort of patients and suggested heterogeneity of MICPCH.

**Results**

Overall, we identified causative or candidate genomic aberrations in 37 of the 41 patients (90.2%) (Table 1). Briefly, 23 patients had point mutations of CASK, nine patients had CNVs affecting CASK and five had aberrations involving other genes. Among all, parental samples were available for 13 patients (Table 1). Their samples were also tested to confirm that all the patients’ mutations were de novo, except for patient 37.

**Subjects**

We recruited 41 patients clinically diagnosed with MICPCH, including 16 patients who have previously been reported [3, 7, 9] (Table 1). All patients were examined and evaluated by clinical dysmorphologists in each hospital and were enrolled in this study if they met the criteria for both microcephaly and pontocerebellar hypoplasia in brain magnetic resonance imaging (MRI) (Fig 1). All the patients were Japanese.

Patient’s clinical features are shown in Table 1. The cohort was largely comprised of females, with only six male patients, and their ages varied between five months to 17 years old at the last follow-up examination. Development has been markedly retarded, and some of them also showed seizures. Only six patients could walk at the time of the evaluation, and only three could speak a few words. While the occipital-frontal circumference (OFC) at birth ranged from normal to severe microcephaly in a few cases, at the last examination most of the patients showed a severe microcephaly (<-3.0SD). Although three cases (patients 36, 37, and 41) had OFC larger than -3.0 SD, we decided to include them in this cohort because their pontocerebellar hypoplasia resembled those of the other patients. Although most patients did not show major anomalies besides microcephaly, some of them also presented with ocular abnormalities and/or muscular hypotonia. From the results of the brain MRI examination, the
| Patient | Gender | Age | OFC (SD) | Developmental delay | Muscular hypotonia | Seizures | Other clinical features | Gene(s) in which mutation was found | Mutation | Inheritance | Previous report |
|---------|--------|-----|----------|---------------------|------------------|----------|-------------------------|---------------------------------|----------|-------------|-----------------|
| 1       | F      | 2y8m | -3.2     | -4.3                | Severe           | +        | -                       | CASK                            | c.79C>T (p.R27*)                | DS         | NA          | Patient 1 in [7]|
| 2       | F      | 1y6m | -1.2     | -3.6                | Severe           | +        | -                       | CASK                            | c.79C>T (p.R27*)                | DS         | NA          |                  |
| 3       | F      | 2y0m | -2.3     | -3.5                | Moderate         | +        | -                       | Bialateral hydronephrosis       | c.316C>T (p.R106*)              | DS         | NA          | Patient 2 in [7]|
| 4       | F      | 4y0m | -9.2     | -9.2                | Very severe      | +        | -                       | CASK                            | c.316C>T (p.R106*)              | DS         | NA          | Patient 3 in [9]|
| 5       | F      | 1y    | -3.6     | -3.6                |                 | -        | -                       | VE                              | c.868G>T (p.E290*)              | DS         | NA          |                  |
| 6       | F      | 2y8m | -2.8     | -4.0                | Severe           | -        | -                       | Severe hyperopia                | c.2632C>T (p.Q878*)             | DS         | dn          | Patient 3 in [7]|
| 7       | F      | 11m   | -0.8     | -3.2                |                 | -        | -                       | CASK                            | c.243_244delTA (p.Y81*)         | DS         | NA          | Patient 4 in [7]|
| 8       | F      | 5m    | -0.9     | -4.5                | Present         | +        | -                       | CASK                            | c.761_762delCT (p.S246*)        | DS         | dn          |                  |
| 9       | F      | 15y   | -6.4     | -6.4                | Severe           | +        | +                       | CASK                            | c.1006_1012delACCTCCT (p.T336Qfs*23) | DS       | NA          |                  |
| 10      | F      | 4y2m  | -4.0     | -4.0                | Severe           | +        | -                       | CASK                            | c.2103delT (p.F701Lfs*26)       | DS         | NA          |                  |
| 11      | F      | 1y    | -1.4     | -6.0                | Severe           | +        | -                       | CASK                            | c.1677dupG (p.R560Afs*20)       | WES        | dn          |                  |
| 12      | F      | 11y   | -6.8     | -6.8                | Severe           | +        | -                       | CASK                            | c.1896dupC (p.Q633Lfs*2)        | DS         | NA          |                  |
| 13      | F      | 17y   | -1      | -6.0                | Severe           | +        | -                       | CASK                            | c.2509delT (p.L857*)            | DS         | NA          |                  |
| 14      | F      | 7y    | -0.3     | -4.0                | Severe           | +        | -                       | CASK                            | c.173_173+1delGG                | DS         | NA          | Patient 2 in [9]|
| 15      | F      | 7y8m  | -3.4     | -4.5                | Severe           | -        | -                       | CASK                            | c.357-1G>A                     | DS         | dn          | Patient 5 in [7]|
| 16      | F      | 1y    | -4.8     | -4.8                | Moderate         | +        | -                       | CASK                            | c.1582>G>A                     | DS         | NA          |                  |
| 17      | F      | 14y   | -0.4     | -6.0                | Moderate         | -        | -                       | CASK                            | c.2040-1G>C                     | DS         | dn          | Patient 6 in [7]|
| 18      | F      | 3y    | -3.0     | -3.0                |                 |          | -                       | CASK                            | c.2302+1G>T                     | DS         | NA          |                  |
| 19      | F      | 11y   | -5.0     | -5.0                | Moderate         |          | -                       | CASK                            | c.2302+1delT                    | DS         | NA          | Patient 1 in [9]|
| 20      | F      | 8y    | -3.0     | -3.0                |                 |          | -                       | CASK                            | c.1910G>A                      | DS         | NA          | Patient 4 in [7]|
| 21      | M      | 2y    | -1      | -4.1                | Severe           | +        | -                       | CASK                            | c.1061T>C (p.L354P)             | DS         | NA          | Patient 16 in [9]|
| 22      | M      | 4y1m  | -4.9     | -4.9                |                 |          | -                       | CASK                            | c.371G>C (p.R106P)              | DS         | dn          |                  |
| 23      | M      | 2y    | -1.1     | -3.2                | Severe           | +        | -                       | CASK                            | c.1493_1503+10delATGAACCAATGTAAGTAGAinsGG (p.D498Gfs*12) | DS       | NA          |                  |
| 24      | F      | 5y    | -3.1     | -6.0                | Severe           | -        | -                       | CASK                            | ar Xp11.4p1.3 (41,500,243–45,480,187)x1 | MA       | dn          | Patient in [3]|
| 25      | F      | 1y7m  | -4.3     | -4.6                | Severe           | +        | -                       | CASK                            | ar Xp11.4p1.3 (41,009,876–44,100,501)x1 | MA       | dn          | Patient 7 in [7]|
| 26      | F      | 6y7m  | -0.8     | -3.2                | Severe           | +        | -                       | CASK                            | ar Xp11.4p1.3 (41,618,908–43,755,475)x1 | MA       | dn          |                  |
| 27      | F      | 2y0m  | -1.3     | -4.0                | Moderate         | -        | -                       | CASK                            | ar Xp11.4p1.3 (41,337,795–42,468,013)x1 | MA       | dn          | Patient 8 in [7]|
| 28      | F      | 4y    | -2      | -4.0                |                 |          | -                       | CASK                            | ar Xp11.4p1.3 (41,145,925–46,090,321)x1 | MA       | NA          |                  |
| 29      | F      | 12y8m | -4.8     | -8.0                | Severe           | +        | -                       | Glaucoma, PHPV                   | ar Xp11.4p1.3 (41,163,139–44,592,980)x1 | MA       | NA          |                  |
| 30      | F      | 12y   | -1.9     | -5.4                | Severe           | +        | -                       | CASK                            | ar Xp11.4p1.3 (41,405,593–41,570,391)x3 | MA       | NA          | Patient 9 in [7]|
| 31      | F      | 7y2m  | -1.5     | -5.2                | Severe           | +        | -                       | Internal strabismus             | ar Xp11.4p1.3 (41,540,922)x3     | MA       | dn          | Patient 10 in [7]|
| 32      | F      | 0     | -4.4     | -4.4                | Severe           |          | -                       | CASK                            | ar Xp11.4p1.3 (41,442,660–41,527,850)x3 | MA       | NA          |                  |

(Continued)
### Table 1. (Continued)

| Patient | Gender | Age | OFC (SD) | Developmental delay | Muscular hypotonia | Seizures | Other clinical features | Gene(s) in which mutation was found | Mutation Description | Detectiona | Inheritanceb | Previous report |
|---------|--------|-----|----------|---------------------|-------------------|----------|------------------------|-----------------------------------|---------------------|-------------|----------------|----------------|
| 33      | F      | 10y | -0.9     | -3.5                | Severe            | -        | + Hyoplastic CC, minor anomalies1 | HDAC2, MAROKS             | arr 6q21p22.31(109,497,085–122,505,593)x1 | MA          | NA            |                |
| 34      | F      | 2y  | -4.0     | Severe              | +                 |  |  | Hirsutism, characteristic face | RELN                | c.4918A>G (p.1640V) | TR          | NA            |                |
| 35      | M      | 4y6m | -5.0     | Severe              | +                 |  |  | Hypoplastic CC            | RELN                | c.7093G>A (p.V2365M) | TR          | NA            |                |
| 36      | M      | 3y  | 0.2      | -1.7                | Severe            | -        | Thick CC                 | ITPR1                | c.7753A>C (p.T2585P) | WES         | dn           |                |
| 37      | F      | 3y  | -0.8     | Moderate            | +                 | - VSD, minor anomalies1h | DYNC1H1, DCTN1 | c.11824C>T (p.P3942S), DCTN1 | c.497C>G (p.S166C) | WES         | pat,mat       |                |
| 38      | F      | -0.6 | -5.2     | Severe              | +                 | + Internal strabismus, VE |  |  | ni                                      | ni                                    |             |              |                |
| 39      | F      | 4y  | -1       | -3.1                | Moderate          | -        | Hyperopia                |  |  | ni                                      | ni                                    |             |              |                |
| 40      | F      | 5y  | normal   | -1                  | Moderate          | -        | -                       |  |  | ni                                      | ni                                    |             |              |                |
| 41      | F      | 5y  | 0.6      |                      |                   | -        | Severe                  |  |  | ni                                      | ni                                    |             |              |                |

SD: standard deviation, ni: not identified
a PHPV: persistent hyperplastic primary vitreous CC: corpus callosum VE: ventricular enlargement
b DS: direct sequencing WES: whole exome sequencing MA: microarray TR: target resequencing
c dn: de novo m: maternal NA: Not available
d The severity has not been estimated correctly because of patient's age.
e Hirsutism, low hairline, arching of eyebrows with sparse lateral third, earlobe sinuses, micrognathia, proximally placed thumbs, brachydactyly and clinodactyly of the 5th fingers
f Widely spaced eyes, downsloated palpebral fissure, Epicanthus, thick and small auricle, short philtrum, cubitus varus, short finger, proximal placement of thumb
g DCTN1 mutation was paternally and DYNC1H1 mutation was maternally inherited, respectively.
h Bilateral, preaxial polysyndactyly of toes, prominent forehead, depressed nasal root

https://doi.org/10.1371/journal.pone.0187191.t001
severity of the pontocerebellar hypoplasia was found to be variable, whereas the size of the corpus callosum tended to be normal [10].

DNA and chromosomes were extracted from peripheral blood by standard methods. A lymphoblastoid cell line (LCL) was also established for all patients and available samples of parents (Table 1) by infecting lymphocytes with an Epstein-Barr virus, as previously described [11].

Point mutation of CASK

The sequencing of the whole coding region of CASK identified point mutations likely to be responsible for the phenotypes in a total of 23 cases (Table 1). Nonsense mutations were detected in six cases: c.79C>T (p.R27*) in patients 1 and 2; c.316C>T (p.R106*) in patients 3 and 4; c.868G>T (p.E290*) and c.2632C>T (p.Q878*) in patients 5 and 6, respectively. Indel mutations introducing a premature stop codon were detected in seven cases: c.243_244delTA (p.Y81*), c.761_762delCT (p.S246*), c.1006_1012delACCTCCT (p.T336Qfs’23), c.2103delT
(p.F701Lfs*26), c.1677dupG (p.R560Afs*20), c.1896dupC (p.C633Lfs*2), and c.2508delT (p.L837) in patients 7 to 13, respectively. Specifically, the mutation in patient 11 was actually identified by WES, as described later. Mutations at the exon-intron junction were found in six cases: c.173_173+1delGG, c.357-1G>TA, c.1582+G>A, c.2040-1G>C, c.2302+1G>T, and c.2302+1delT in patients 14 to 19, respectively. These mutations probably resulted in aberrant splicing, of which we have previously confirmed the presence of aberrant transcripts in patients 15 and 17 [7].

Missense mutations were detected in three cases, and in silico analysis predicted them to be disease-associated variations. The c.1910G>A (p.G637D) variant in patient 20, c.1061T>C (p.L354P) variant in patient 21, and c.317G>C (p.R106P) variant in patient 22 were predicted in silico to be damaging or disease-associated variation by PolyPhen-2, SIFT, or SNPs&GO, respectively, and their REVEL scores were also high (S1 Table).

Among the six male patients, CASK aberrations were identified in three; other than patients 21 and 22 described above, Patient 23 who presented with typical MICPCH (Fig 1) was found to have an indel between exon 15 and intron 15 resulting in a stop codon in a heterozygous-like pattern, despite being male (2A and 2B). This result suggests that the patient had the mutation in a mosaic state. Primer sets specific for the indel mutation amplified a product only in this patient (Fig 2C). Additionally, real-time quantitative PCR with the same primer sets confirmed a decreased copy number of both intact and indel alleles relative to a male control (Fig 2D). Thus, we concluded this patient is a rare case of a somatic mosaic indel mutation.

Fig 2. Detailed analysis of the mosaicism of CASK in patient 23. A Sequence chromatogram showing a heterozygous-like pattern in the latter part of exon 15 (arrow). B Scheme of the indel mutation. Compared with the reference allele (upper), the affected allele (lower) had a 21-bp deletion and a 2-bp insertion at the exon-intron junction of exon 15 and intron 15. C Results of the genomic PCR using WT-specific and indel-specific primer sets in the patient and a male control. The red box indicates a product amplified only in the patient with the indel-specific primer sets. M: marker; phiX174 RF DNA/Hae III Fragments, P: patient 23, C: control, N: negative control, no DNA added. D Real-time quantitative PCR of genomic DNA from patient 23 and male and female controls. While the relative copy number of the male control is naturally approximately half of that of the female control, those amplified with both WT-specific and deletion-specific primers in the patient are also approximately half of that of the male control.

https://doi.org/10.1371/journal.pone.0181791.g002
presumably affecting CASK expression, described as c.1493_1503+10delATGAACCAA
TGGTAAGTAGGAinsGG.

**CNV involving CASK and other candidate genes**

SNP array led to the discovery of heterozygous deletions involving whole or part of the CASK gene in six cases (patients 24 to 29), and intragenic duplications in three cases (patients 30 to 32) (Table 1). We have previously described patients 30 and 31 in detail [7]. In patient 32, oligonucleotide array determined exons 4 and 5 to be duplicated (S1 Fig). In order to precisely map the rearrangement, genomic PCR was performed with a primer combination specific to a tandem duplication structure (S2 Fig), and a product was detected only in the patient (S3 Fig). Sequencing of this product showed that intron 5 was followed by a duplicated intron 4 (S4 Fig), resulting in a shift in the reading frame and thereby producing an aberrant transcript. As a consequence, all intragenic duplications probably also resulted in loss-of-function of CASK.

Fine mapping of the CNVs using primer sets flanking the breakpoint (BP) junctions was performed in seven cases, patients 24–27 and 30–32. One case, patient 25, had a 126-bp sized Alu repeat at the BP (S5 Fig, upper), indicating it was likely mediated by non-allelic homologous recombination (NAHR) [12, 13]. In contrast, one case, patient 26, had no homology at the BP (S5 Fig, middle), therefore the rearrangement might have been induced by non-homologous end joining (NHEJ). The other five cases, patients 24, 27, and 30–32, had a microhomology of 1–3 base pairs at the BP junction (S5 Fig, lower), likely caused by microhomology-mediated break-induced replication (MMBIR). These findings suggest that most of the CNVs were not induced by a specific motif, suggesting CNVs involving CASK are probably non-recurrent (Table 1).

The SNP array analysis also identified a CNV not encompassing CASK in patient 33, who presented with typical MICPCH (Fig 1): a 13-Mb heterozygous deletion at 6q21-q22.31 (Table 1; Fig 3A and 3B). This result is concordant with previous reports of deletion overlapping with this case also showing MICPCH [14, 15]. We confirmed she had no mutations of CASK (data not shown).

**Targeted resequencing**

Among 231 mutations detected in the six cases, only two mutations were in exons of RELN [OMIM: *600514] (S1 Table). One was c.4918A>G (p.I1640V) in patient 34, who is female and shows typical MICPCH (Fig 1), and the other was c.7093G>A (p.V2365M) in patient 35, who is male and also shows typical MICPCH (Fig 1). Both of the mutations were confirmed by direct sequencing (Fig 3C). The substituted isoleucine and valine are highly conserved at least in primates and placental animals (Fig 3D), suggesting that both amino acids are important for RELN function. *In-silico* analyses found p.I1640V not to be damaging (‘tolerated’ by PolyPhen-2 and SIFT, and ‘neutral’ by SNPs&GO), and scores of REVEL and CADD also suggested that mutation was not probably damaging (S2 Table). However, the mutated residue was predicted to be smaller than the wild type (WT), leading to loss of interactions, according to prediction by HOPE. The evaluation of p.V2365M may be vague: it was evaluated to be ‘damaging’ by PolyPhen-2 and SIFT and CADD scores were very high, while SNPs&GO judged it ‘neutral’ and REVEL score was rather low. HOPE predicted the 3D structure to be bigger than the WT and the mutated residue might prefer to be in another secondary structure, thus the local conformation would be slightly destabilized.

**Whole-exome sequencing**

In patient 11 eight single-nucleotide variations (SNVs) and four indel mutations were extracted as candidate mutations. Among them, one insertion of a single guanine, c.1677dupG (p.R560Afs*20)
in exon 18 of CASK caused a frameshift leading to a stop codon (Fig 3E). As the insertion was located at continuous guanines and close to the exon-intron junction, it might have been over-looked in the previous steps by the direct sequencing and targeted resequencing.

In patient 36, candidate SNVs were identified in three genes, ITPR1, WNK3, and CYCL1. Among them, c.7753A>C (p.T2585P) in exon 58 of ITPR1 [OMIM: *147265] was functionally the strongest candidate (Fig 3E). Heterozygous mutations of ITPR1 are known to cause
spinocerebellar ataxia (SCA) 15 [606658] and 29 [117360]. Specifically, SCA29 is characterized by a psychomotor delay with an onset in the infantile period and an atrophic cerebellum, but not severe microcephaly [16], which is consistent with the mild microcephaly shown by patient 36 (Table 1, Fig 1). In total, in-silico analyses suggested this variant is probably disease-associated (S2 Table), and HOPE predicted that the mutation introduces a more hydrophobic residue at this position, hence the 3D structure of the protein might disrupt an α-helix, impairing the correct folding. Taken together, these findings indicate that this mutation may account for the patient’s etiology.

In patient 37, since the de novo analysis and compound heterozygous variant filtering failed to indicate a functionally significant candidate gene, we performed a protein-protein network analysis in order to assess possible interactions between the mutated genes found in the patient. Thus, all novel SNVs extracted in patient 37 were evaluated by the STRING database (http://string-db.org/), which indicated a close interaction between DYN2H1 [OMIM: *600112] and DCTN1 [*601143], both being missense variants (Fig 3F, S6 Fig). While the maternally-inherited c.11824C>T (p.P3942S) variant in DYN2H1 was predicted in silico as benign to neutral with lower REVEL score, the paternally-inherited c.497C>G (p.S166C) mutation in DCTN1 was predicted to be neutral to damaging (S2 Table). Despite the fact that the in-silico predictions did not show strong evidence of pathogenicity of the variants alone, the possibility remains that the combined occurrence of both variants in the same protein complex might be associated with the patient’s phenotype.

Discussion

Since the first report of CASK aberrations associated with MICPCH, more than 50 cases have been reported [4–7]. Here we summarized our investigation of 41 MICPCH cases, and in total we were able to identify causative or candidate genomic aberrations in 37 out of 41 cases (90.2%) (Table 1). Among the 37 positive cases, 23 cases (57.6%) had a point mutation of CASK and nine cases (27.3%) had CNV involving CASK (Table 1, Fig 4A and 4B). We also found five cases, two males and three females, with aberrations in other causative and/or candidate genes. For 13 cases whose parental samples were available, analysis of the parental samples showed that all the mutations were de novo, except patient 37 who may have compound mutations from both of the parents (see below).

Mapping of the breakpoint junctions of seven cases with the CNVs including CASK revealed that they might have been originated by several mechanisms of genomic rearrangements, namely NAHR, NHEJ and MMBIR (S2A–S2C Fig), suggesting that CNVs involving CASK are generally non-recurrent. This non-recurrent nature of CASK CNVs is concordant with the fact that most CASK-related point mutations arise de novo.

Atypical cases in this cohort were represented by three male cases found with CASK aberrations. Two cases (patient 21 and 22) had a missense mutation [9], and the other case (patient 23) was a somatic mosaic of WT and indel alleles (Fig 2). Recent studies have shown that CASK mutations in male patients lead to a broad spectrum of phenotypes including MICPCH. While missense mutations corresponding to functional change of the CASK protein causes non-syndromic intellectual disability [17–19] or FG syndrome [20], a decrease in the normal expression appears to correlate with the manifestation of MICPCH [8]. The complete loss of CASK expression was associated with a severe MICPCH phenotype and likely caused the reduced viability or in utero lethality [4, 8], which is consistent with the neonatal lethality of Cask knockout mice [21]. Thus, CASK-inactivating mutations in mosaic state (like the case of patient 23) might be able to escape early lethality due to incomplete loss of CASK expression, thereby resulting in typical MICPCH.
Aside from CASK, we also found another known gene in which mutations are causative for MICPCH, through the identification of an ITPR1 mutation in patient 36 by WES (Fig 3E). ITPR1 has previously been established as a causative gene of SCA29 associated with psychomotor delay and atrophy of the cerebellum, likely consistent with the brain malformation of patient 36 [16]. However, it may be distinguished from typical MICPCH caused by CASK mutation by a relatively milder microcephaly, thicker corpus callosum and non-atrophic brainstem.

Our investigation found a few genes that might be associated with MICPCH. Our findings in patient 33 support evidence linking the deletion of 6q21 to MICPCH (Fig 3A and 3B), concordant with previous reports of typical MICPCH cases with deletion at 6q21 [14, 15]. In particular, Case 7 reported by Rosenfeld showed typical MICPCH and had the smallest deletion, including only three protein-coding genes, MARCKS [OMIM: *602940], HDAC2 [’605164], and HS3ST5 [’609407]. MARCKS is reported to bind actin to support cytoskeletons, and HDAC2 is a histone deacetylase that acts as a suppressor of the expression of other genes [22]. While its function remains uncertain, HS3ST5 is highly expressed in the fetal brain [23]. These findings strongly suggest that haploinsufficiency of HDAC2, MARCKS, and possibly HS3ST5
may be relevant to MICPCH, even though Hdac2 or Marcks mutant mice showed conflicting phenotypes. Marcks+/− mice showed no brain abnormality, while Marcks−/− resulted in perinatal lethality with abnormal brain development [24]. Both heterozygous and homozygous Hdac2-deficient mice were viable and had normal brains, and additionally, the spine density was markedly increased in Hdac2−/− mice [25]. On the other hand, mice with conditional knockout of both Hdac2 and Hdac1, a homologous gene of Hdac2, showed severe hippocampal and cerebellar abnormalities [26]. Although these results suggested that either HDAC2 or MARCKS alone might not cause brain malformations, haploinsufficiency of both genes may be relevant to MICPCH due to the collapse of the interaction between them.

Targeted resequencing screening only detected heterozygous mutations in RELN in two cases, of uncertain pathogenicity (Fig 3C). RELN encodes a secreted protein playing an important role in neural migration in the developing brain and spinal cord [27, 28]. While homozygous loss-of-function mutations of RELN cause lissencephaly with cerebellar hypoplasia [OMIM: #257320] [29, 30], heterozygous missense mutations of RELN cause autosomal-dominant lateral temporal epilepsy (ADLTE) with no brain anomaly [31]. Although the nature of the current mutations remain uncertain, an interesting report that CASK regulates the expression of RELN through interactions with TBR1 may suggest that RELN would be also associated with MICPCH [32].

WES analysis also identified an interesting pair of mutations of DYNC1H1 and DCTN1 in patient 37 (Fig 3F), respectively inherited from the mother and father. DYNC1H1 encodes a member of the cytoplasmic dynein heavy chain [33], while DCTN1 encodes p150(Glued), the largest subunit of dynactin [34, 35]. The dynein–dynactin complex plays an important role during mitosis and is necessary for synapse stabilization [36]. Heterozygous mutations in the motor domain of DYNC1H1 have been associated with autosomal dominant mental retardation-13 (MRD13) with neuronal migration defects [OMIM: #614563], in which a subset of patients also present with microcephaly along with a small cerebellum and/or brainstem [37, 38]. However, the vast majority of the reported mutations were de novo. Mutations in DCTN1 cause distal hereditary motor neuronopathy type VIIB [OMIM: *607641] and, so far, there is no association with brain malformations. Despite the uncertainty of the clinical significance of both variants, one might speculate the possibility of a ‘double-hit’ effect similar to a digenic inheritance model, in which variant genotypes at two loci (often involving interacting proteins) explain the phenotypes of some patients more clearly than the genotypes at one locus alone [39]. This tentative etiology may also explain the reason why the phenotype of patient 37 is relatively milder (Table 1). Nevertheless, further studies are needed to assess the combined effect of the two variants in the stability of the dynein–dynactin complex.

Our present study comprehensively explained the etiologies of MICPCH using several genomic analysis techniques. Not only did it identify CASK but also other genes involved in the etiology of MICPCH. Our findings demonstrate that MICPCH is a genetically heterogeneous condition, in which CASK inactivating mutations appear to account for the majority of MICPCH cases and with severer phenotypes, while the non-CASK mutation cases tend to have milder microcephaly. For the remaining cases, WES or WGS analysis may identify the undiscovered causative genes.

Materials and methods

Informed consent

Written informed consent was obtained from the parents of all the subjects. The consent form includes an agreement to have their clinical details and genetic analyses published without personal information.
Direct sequencing of \textit{CASK}

Point mutations within the coding region of \textit{CASK} were analyzed by exon amplification and direct sequencing as previously described [7].

Microarray analysis

For patients in whom no pathogenic \textit{CASK} point mutation was found, SNP array (HumanOmniaExpress-12 v1.0; Illumina, San Diego, CA, USA) was performed in order to detect genomic copy number variant (CNV) involving \textit{CASK}. Oligonucleotide array (Human CGH Array 2.1Mb; Roche-Nimblegen, Madison, WI, USA) was subsequently applied to the positive cases to better determine the extent of the CNVs. DNA labeling, hybridization and washing were carried out according to the directions provided by the manufacturer. All CNVs were confirmed by fluorescence in situ hybridization (FISH), performed as previously described [40].

Genomic PCR and real-time quantitative PCR

Genomic PCR was performed to amplify and sequence the breakpoint junctions of the CNVs. We also performed genomic PCR to confirm the presence of mosaicism in patient 19 by designing intact-specific and mutation-specific primer sets (S3 Table). The same primer sets were used for real-time quantitative PCR assay in order to determine the proportion of mosaic alleles on the genomic DNA of the patient, using the 7500 Real-Time PCR System (Applied Biosystems, Grand Island, NY, USA) and KAPA SYBR® FAST qPCR Master Mix (KAPA Biosystems, Wilmington, MA, USA), according to the manufacturers’ instructions.

Targeted resequencing

Samples of six patients (patients 11, 34, 35, 38, 39, and 41) in whom neither point mutation of \textit{CASK} nor CNVs involving \textit{CASK} had been identified in the previous steps were subjected to targeted resequencing (amplicon sequencing) on the Ion Torrent PGM platform (Life Technologies, Carlsbad, CA, USA). Primer sets targeting the whole \textit{CASK} region, including all exons including 5’ and 3’ untranslated regions (UTR), introns, promoter region, and all exons of 16 candidate genes interacting with \textit{CASK} or corresponding to pontocerebellar hypoplasia in the literature (Table 2), were designed using the manufacturer’s AmpliSeq primer design tool (http://www.ampliseq.com). Library preparation and sequencing were performed according to the manufacturer’s protocol. Base-calling and alignment to the human reference genome (GRCh37/hg19) were carried out using Torrent Suite 3.6 (Life Technologies). Variant detection was performed with the Variant Caller plug-in software of Torrent Suite.

Whole-exome sequencing

Among the eight negative cases after the targeted resequencing, we applied whole-exome sequencing (WES) for three cases (patients 11, 36, and 37) whose parental samples were available. Exome library was prepared using the SureSelect Human All Exon V5+UTRs Kit (Agilent, Santa Clara, CA, USA) and sequenced using the HiSeq2500 platform with Cluster/SBS kit v3 (Illumina). We extracted candidate mutations as follows: \textit{de novo} variations were first extracted by comparing the sequence data between the trio of patient and parents, followed by filtering of variants with low read-depth (RD<4) or those occurring at non-coding regions. Next, variations observed in healthy populations were excluded in reference to a database of known SNPs, dbSNP [http://www.ncbi.nlm.nih.gov/SNP/], ExAC browser [http://exac.broadinstitute.org/], and Human Genetic Variation Database (HGVD), which provides...
Japanese genomic variants [http://www.genome.med.kyoto-u.ac.jp/SnpDB/]. The narrowed-down candidate mutations were confirmed by direct sequencing.

**Bioinformatics analysis of sequence variants**

For *in-silico* prediction of a possible deleterious effect of missense mutations, we used the following online tools: Polymorphism Phenotyping v2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2), Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/), SNPs&GO (http://snps.biofold.org/snps-and-go/), REVEL [48], CADD (http://cadd.gs.washington.edu/home),

| Gene   | Position | Exons | Target | Corresponding disorder(s) | Inheritance | Comment | Reference |
|--------|----------|-------|--------|----------------------------|-------------|---------|-----------|
| CASK   | Xp11.4   | 27    | whole gene | MICPCH            | XD          | Causative gene |          |
| HDAC2  | 6q21     | 14    | all exons | MICPCH            | AD          | Candidate gene |          |
| TBR1   | 2q24.2   | 6     | all exons | Coactivator of CASK |            |          | [32]      |
| RELN   | 7q22.1   | 65    | all exons | Lissencephaly      | AR          | Causative gene | [30]      |
| VLDLR  | 9p24.2   | 19    | all exons | CAMRQ1            | AR          | Causative gene; a part of RELN signaling pathway | [41]      |
| DAB1   | 1p32.2   | 15    | all exons | Component of RELN signaling pathway |            |          |           |
| LRP8   | 1p32.3   | 19    | all exons | Component of RELN signaling pathway |            |          |           |
| FYN    | 6q21     | 11    | all exons | Component of RELN signaling pathway |            |          |           |
| VRK1   | 14q32.2  | 12    | all exons | PCH1A            | AR          | Causative gene | [42]      |
| EXOSC3 | 9p13.2   | 4     | all exons | PCH1B            | AR          | Causative gene | [43]      |
| TSEN54 | 17q25.1  | 11    | all exons | PCH2A, PCH4      | AR          | Causative gene | [44]      |
| TSEN2  | 3p25.3   | 11    | all exons | PCH2B            | AR          | Causative gene | [44]      |
| TSEN34 | 19q13.42 | 5     | all exons | PCH2C            | AR          | Causative gene | [44]      |
| SEPSECS| 4p15.2   | 11    | all exons | PCH2D            | AR          | Causative gene | [45]      |
| RARS2  | 1p32.3   | 1     | all exons | PCH6             | AR          | Causative gene | [46]      |
| CHMP1A | 16q24.3  | 6     | all exons | PCH8             | AR          | Causative gene | [47]      |
| BMI1   | 10p12.2  | 9     | all exons | Regulated by CHMP1A |            |          | [47]      |

PCH: pontocerebellar hypoplasia  
CAMRQ1: cerebellar ataxia, mental retardation, and dysequilibrium syndrome  
AD: autosomal dominant  
AR: autosomal recessive  
XD: X-linked dominant

https://doi.org/10.1371/journal.pone.0181791.t002

Japanese genomic variants [http://www.genome.med.kyoto-u.ac.jp/SnpDB/]. The narrowed-down candidate mutations were confirmed by direct sequencing.
and HOPE (http://www.cmbi.ru.nl/hope/). The STRING database (http://string-db.org/) was used to assess the presence of functional interactions between proteins.

Ethics statement

This study was approved by the Research Ethics Committee of Tokyo Medical and Dental University and all institutions involved in this project; The Ethics Committee of Central Hospital, Aichi Human Service Center, The Ethics Committee of the Ryukyus Graduate School of Medicine, Institutional Review Board of Kameda Medical Center, Institutional Review Board of Kameda Medical Center, Ethical Committee of Kanagawa Children Medical Center, The Institutional Review Board of Hokkaido Medical Center for Child Health and Rehabilitation, and The Ethical Review Board of Osaka Medical Center and Research Institute for Maternal and Child Health.

Supporting information

S1 Fig. Result of the oligonucleotide array of patient 32. An 85.19 kb duplication at Xp11.4 was detected (red circle). The result is described as follows: arr Xp11.4(41,442,660–41,527,850)x3. (TIF)

S2 Fig. Scheme of the expected tandem duplication in patient 32. The Box with a number indicate each exon. The pair of black triangles indicate the designed primer set for the genomic PCR. (TIF)

S3 Fig. Genomic PCR using the duplication-specific primer sets in patient 32. The arrow denotes the duplication-specific product. M: marker; phiX174 RF DNA/Hae III Fragments, P: patient 32, C: control, N: negative control, no DNA added. (TIF)

S4 Fig. Sequences around the breakpoint of the duplication of patient 32. P: sequence around the breakpoint of the patient, Ref-4 and Ref-5: reference sequences of a part of introns 4 and 5, respectively. (TIF)

S5 Fig. Schematic illustrations showing mechanisms producing the breakpoints of patient 21, 22, and 23. The size of each component doesn’t reflect the original proportion. (Upper) Two blue boxes denote Alu repeats flanking the deletion in patient 21. In the sequence of both proximal and distal Alu repeats, 118 of 126 bp (93.7%) are homologous, which likely induced the non-allelic homologous recombination (NAHR), resulting in the deletion. (Middle) There was no homology around the BP in patient 22 and the deletion might have been induced incidentally, while 10-bp sequences of unknown origin were observed at the BP. (Lower) Two yellow boxes denote 3-bp microhomologies, which likely induced the deletion in patient 23. (TIF)

S6 Fig. Scheme of protein interactions according to STRING. The WES analysis identified mutations including nonsense, splice-site, frameshift, and missense mutations, in those genes in patient 37. The enlarged panel shows a direct interaction between DYNC1H1 and DCTN1. (TIF)

S1 Table. Detected mutations in the target resequencing. (TIF)
Acknowledgments

We thank Kazuto Kato, Shoji Tsuji, and Shinichi Morishita for their kind cooperation with whole exome sequencing, and Kanako Maizuru for detailed clinical information. We also would like to thank Ayako Takahashi and Rumi Mori for their kind technical assistance.

Author Contributions

**Conceptualization:** Shin Hayashi, Johji Inazawa.

**Data curation:** Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto.

**Formal analysis:** Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Nobuhiko Okamoto.

**Funding acquisition:** Shin Hayashi, Johji Inazawa.

**Investigation:** Shin Hayashi, Daniela Tiaki Uehara, Nobuhiko Okamoto.

**Methodology:** Shin Hayashi.

**Project administration:** Johji Inazawa.

**Resources:** Seiji Mizuno, Yasutugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto.

**Software:** Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto.

**Supervision:** Nobuhiko Okamoto, Johji Inazawa.

**Validation:** Shin Hayashi.

**Visualization:** Shin Hayashi.

**Writing – original draft:** Shin Hayashi.

**Writing – review & editing:** Shin Hayashi, Daniela Tiaki Uehara, Johji Inazawa.

References

1. Stevenson D, Laverty HG, Wenwieser S, Douglas M, Wilson JB. Mapping and expression analysis of the human CASK gene. Mamm Genome. 2000; 11:934–7 PMID: 11003712

2. Hsueh YP. The role of the MAGUK protein CASK in neural development and synaptic function. Curr Med Chem. 2006; 13:1915–27 PMID: 16842202

3. Hayashi S, Mizuno S, Migita O, Okuyama T, Makita Y, Hata A, et al. The CASK gene harbored in a deletion detected by array-CGH as a potential candidate for a gene causative of X-linked dominant mental retardation. Am J Med Genet A. 2008; 146A:2145–51. https://doi.org/10.1002/ajmg.a.32433 PMID: 18629876

4. Najm J, Horn D, Wimberger I, Golden JA, Chizhikov VV, Sudi J, et al. Mutations of CASK cause an X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and cerebellum. Nat Genet. 2008; 40:1065–7. https://doi.org/10.1038/ng.194 PMID: 19165920

5. Moog U, Kutsche K, Kortum F, Chilian B, Bierhals T, Apeshiotis N, et al. Phenotypic spectrum associated with CASK loss-of-function mutations. J Med Genet. 2011; 48:741–51. https://doi.org/10.1136/jmedgenet-2011-100218 PMID: 21954287
6. Burglen L, Chantot-Bastaraud S, Garel C, Milh M, Touraine R, Zanni G, et al. Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient. Orphanet J Rare Dis. 2012; 7:18. https://doi.org/10.1186/1750-1172-7-18 PMID: 22452838

7. Hayashi S, Okamoto N, Chinen Y, Takanashi J, Makita Y, Hata A, et al. Novel intragenic duplications and mutations of CASK in patients with mental retardation and microcephaly with pontine and cerebellar hypoplasia (MICPCH). Hum Genet. 2012; 131:99–110. https://doi.org/10.1007/s00439-011-1047-0 PMID: 21735175

8. Moog U, Bierhals T, Brand K, Bautsch J, Biakup S, Brune T, et al. Phenotypic and molecular insights into CASK-related disorders in males. Orphanet J Rare Dis. 2015. 10:44. https://doi.org/10.1186/s13023-015-0256-3 PMID: 25886057

9. Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, et al. Clinical and radiological features of Japanese patients with a severe phenotype due to CASK mutations. Am J Med Genet A. 2012; 158A:3112–8. https://doi.org/10.1002/ajmg.a.35640 PMID: 23165780

10. Takanashi J, Arai H, Nabatase M, Hirai S, Hayashi S, Inazawa J, et al. Neuoradiologic Features of CASK Mutations. AJNR Am J Neuroradiol. 2010; 31:1619–22. https://doi.org/10.3174/ajnr.A2173 PMID: 20595373

11. Saito-Ohara F, Fukuda Y, Ito M, Agarwala KL, Hayashi M, Matsuo M, et al. The Xq22 Inversion Breakpoint Interrupted a Novel Ras-like GTPase Gene in a Patient with Duchenne Muscular Dystrophy and Profound Mental Retardation. Am J Hum Genet. 2002; 71:637–45 https://doi.org/10.1086/342208 PMID: 12145744

12. Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet. 2005; 1:e49 https://doi.org/10.1371/journal.pgen.0010049 PMID: 16444292

13. Stankiewicz P, Lupski JR. Structural Variation in the Human Genome and Its Role in Disease. Annu Rev Med. 2010; 61:437–55. https://doi.org/10.1146/annurev-med-100708-204735 PMID: 20059347

14. Rosenfeld JA, Amrom D, Andermann E, Andermann F, Veilleux M, Curry C, et al. Genotype-phenotype correlation in interstitial 6q deletions: a report of 12 new cases. Neurogenetics. 2012; 13:31–47. https://doi.org/10.1007/s10048-011-0306-5 PMID: 22218741

15. Tassano E, Mirabelli-Badenier M, Veneselli E, Puliti A, Lerone M, Vaccari CM, et al. Clinical and molecular characterization of a patient with interstitial 6q21q22.1 deletion. Mol Cytogenet. 2015. https://doi.org/10.1186/s13039-015-0134-7 PMID: 26052347

16. Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, et al. Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. Orphanet J Rare Dis. 2012; 7:67. https://doi.org/10.1186/1750-1172-7-67 PMID: 22986007

17. Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SGM, Vermeschi JR, et al. Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. Hum Mutat. 2007; 28:1034–42 https://doi.org/10.1002/humu.20564 PMID: 17546640

18. Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. 2009; 41:535–43. https://doi.org/10.1038/ng.367 PMID: 19377476

19. LaConte LE, Chavan V, Mukherjee K. Identification and glycerol-induced correction of misfolding mutations in the X-linked mental retardation gene CASK. PLoS One. 2014; 9:e88276. https://doi.org/10.1371/journal.pone.0088276 PMID: 24505460

20. Piluso G, D’Amico F, Saccone V, Bismuto E, Rotundo IL, Di Domenico M, et al. A missense mutation in CASK causes FG syndrome in an Italian family. Am J Hum Genet. 2009; 84:162–77. https://doi.org/10.1016/j.ajhg.2008.12.018 PMID: 19200522

21. Atasoy D, Schoch S, Ho A, Nadasay KA, Liu X, Zhang W, et al. Deletion of CASK in mice is lethal and impairs synaptic function. PNAS. 2007; 104:2525–30 https://doi.org/10.1073/pnas.0611003104 PMID: 17287346

22. Zhang Y, Sun ZW, Iratni R, Erdjument-Bromage H, Tempst P, Hampsey M, et al. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell. 1998; 1:1021–31 PMID: 9651585

23. Mochizuki H, Yoshida K, Gotoh M, Sugiooka S, Kikuchi N, Kwon YD, et al. Characterization of a heparan sulfate 3-O-sulfotransferase-5, an enzyme synthesizing a tetrasulfated disaccharide. J Biol Chem. 2003; 278:26780–7 https://doi.org/10.1074/jbc.M301861200 PMID: 12740361

24. Stumpo DJ, Bock CB, Tuttle JS, Blackshear PJ. MARCKS deficiency in mice leads to abnormal brain development and perinatal death. PNAS. 1995; 92:944–8 PMID: 7892670
25. Guan JS, Haggarty SJ, Giaconetti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009; 459:55–60. https://doi.org/10.1038/nature07925 PMID: 19424149

26. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. PNAS. 2009; 106:7876–81. https://doi.org/10.1073/pnas.0902750108 PMID: 19380719

27. D’Arcangelo G, Homayouni R, Keshvarya L, Rice DS, Sheldon M, Curran T. Reelin is a ligand for lipoprotein receptors. Neuron. 1999; 24:471–9 PMID: 10571240

28. Yip JW, Yip YP, Nakajima K, Capriotti C. Reelin controls position of autonomic neurons in the spinal cord. PNAS. 2000; 97:8612–6 https://doi.org/10.1073/pnas.150040497 PMID: 10880573

29. Zaki M, Shehab M, El-Aleem AA, Abdel-Salam G, Koeller HB, Iliny Y, et al. Identification of a novel recessive RELN mutation using a homozygous balanced reciprocal translocation. Am J Med Genet. 2007; 143A:939–944 https://doi.org/10.1002/ajmg.a.31667 PMID: 17431900

30. Hong SE, Shugart YY, Huang DT, Shawhan SA, Grant PE, Hourihane JO, et al. Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with RELN mutations. Nat Genet. 2000; 26:93–96 https://doi.org/10.1038/77924 PMID: 10973257

31. Dazzo E, Fanciulli M, Serioli E, Minervini G, Pulitano P, Binelli S, et al. Heterozygous reelin mutations cause autosomal-dominant lateral temporal epilepsy. Am J Hum Genet. 2015; 96:992–1000. https://doi.org/10.1016/j.ajhg.2015.04.020 PMID: 26046367

32. Hsueh YP, Wang TF, Yang FC, Sheng M. Nuclear transcription and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2. Nuclear transcription and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2. Nature. 2000; 404:298–302 https://doi.org/10.1038/35005118 PMID: 10749215

33. Mikami A, Paschal BM, Mazumdar M, Vallee RB. Molecular cloning of the retrograde transport motor cytoplasmic dynein (MAP 1C). Neuron. 1993; 10:787–96 PMID: 7684236

34. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. PNAS. 2009; 106:7876–81. https://doi.org/10.1073/pnas.0902750108 PMID: 19380719

35. Hayashi S, Kurosa wa K, Imoto I, Mizutani S, Inazawa J. Detection of cryptic chromosome aberrations in a patient with a balanced t(1;9)(p34.2;p24) by array-based comparative genomic hybridization. Genomics. 1996; 31:398–9 https://doi.org/10.1006/geno.1996.0068 PMID: 8838327

36. Hammesfahr B, Kollmar M. Evolution of the eukaryotic dynactin complex, the activator of cytoplasmic dynein. BMC Evol Biol. 2012; 12:95. https://doi.org/10.1186/1471-2148-12-95 PMID: 22726940

37. Poirier K, Lebrun N, Broix L, Tian G, Saillourn C, Boschero n C, et al. Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat Genet. 2013; 45:639–47. https://doi.org/10.1038/ng.2613 PMID: 23603762

38. Schäffer AA. Digenic inheritance in medical genetics. J Med Genet. 2013; 50:641–52. https://doi.org/10.1136/jmedgenet-2013-101713 PMID: 23785127

39. Hayashi S, Kurosawa K, Imoto I, Mizutani S, Inazawa J. Detection of cryptic chromosome aberrations in a patient with a balanced t(1;9)(p34.2;p24) by array-based comparative genomic hybridization. Am J Med Genet A. 2005; 139:32–36 https://doi.org/10.1002/ajmg.a.30982 PMID: 16222686

40. Renbaum P, Kellerman E, Jaron R, Geiger D, Segel R, Lee M, et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am J Hum Genet. 2005; 10:97–102. https://doi.org/10.1086/428453 PMID: 15650922

41. Boycott KM, Flavelle S, Bureau A, Glass HC, Fukushima TM, Wirrell E, et al. Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. Am J Hum Genet. 2005; 77:475–83. https://doi.org/10.1086/444400 PMID: 16080122

42. Renbaum P, Kellerman E, Jaron R, Geiger D, Segel R, Lee M, et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am J Hum Genet. 2005; 85:281–9. https://doi.org/10.1086/430020 PMID: 16222686

43. Wan J, Youshaw M, Mamsa H, Rudnik-Schoenborn S, Menezes MP, Hong JE, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012; 44:704–8. https://doi.org/10.1038/ng.2254 PMID: 22544365

44. Buddes BS, Namavar Y, Barth PG, Poll-The BT, Nürnberg G, Becker C, et al. IRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nat Genet. 2008; 40:1113–8. https://doi.org/10.1038/ng.204 PMID: 18711368

45. Agamy O, Ben Zeve B, Lev D, Marcus B, Fine D, Su D, et al. Mutations disrupting selenocysteine formation cause progressive cerebellot-cerebral atrophy. Am J Hum Genet. 2010; 87:538–44. https://doi.org/10.1016/j.ajhg.2010.09.007 PMID: 20920667
46. Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, et al. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet. 2007; 81:857–62. https://doi.org/10.1086/521227 PMID: 17847012

47. Mochida GH, Ganesh VS, de Michelena MI, Dias H, Atabay KD, Kathrein KL, et al. CHMP1A encodes an essential regulator of BMI1-INK4A in cerebellar development. Nat Genet. 2012; 44:1260–4. https://doi.org/10.1038/ng.2425 PMID: 23023333

48. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. 2016; 99:877–885. https://doi.org/10.1016/j.ajhg.2016.08.016 PMID: 27666373